In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated ...

QIAGEN today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The ...

Owwww, howls your child while holding its ear and crying. Recent findings can lead to the development of a vaccine to protect against a very common type of ear infection.

This important study presents a thoughtful design and characterization of chimeric influenza hemagglutinin (HA) head domains combining elements of distinct receptor-binding sites. The results provide ...

Although heart cells and skin cells contain identical instructions for creating proteins encoded in their DNA, they're able ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

Recent research has uncovered a fascinating mechanism in the nematode worm C. elegans that could have profound implications ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...